We want you to feel inspired every day. We’re future-focused and our business is growing. We succeed together through passion, commitment and teamwork, and so can you. We are currently recruiting for an Analytical Scientists at various levels to join the Process Development (PD) team. The purpose of these roles is to plan, execute, and report the results of analytical assays, and to support other members of the Group as needed to aid the Group Leader in meeting Group/Department objectives. Oxford Biomedica’s PD team consists of experienced scientists and engineers that have extensive expertise in all aspects of upstream and downstream development, and analytical testing. PD take processes from the laboratory “bench” scale and apply process expertise and engineering fundamentals for delivery to Manufacturing. Your responsibilities in this role would be: • Performing analytical assays to support upstream and downstream process development activities, to inform process understanding and to deliver process characterisation activities. • Carrying out multiple laboratory-based assays (such as, but not limited to: ELISAs, plate-based assays, cell-based assays, nucleic acid extractions and qPCR) each week and completing the data processing and reporting for these assays per the schedule. • Contributing to trouble shooting and technical investigations. • Contributing to the writing, revision and review SOPs and technical reports. We are looking for: • Minimum BSc Degree programme level and/or relevant experience. • Practical experience in a range of bioprocess analytical techniques, such as but not limited to, cell-based assays, nucleic acid extractions, qPCR, and ELISA. • Experience in the following areas will be considered an advantage: flow cytometry, HPLC, cell culture and aseptic technique. • You to demonstrate OXB’s core values of: responsible, responsive, resilience, and respect to deliver high-quality analytical assays in a timely manner. • Fluency in written and spoken English. About Us: Oxford Biomedica is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise. What’s in it for you: • Highly competitive total reward packages • Wellbeing programmes • Development opportunities • Welcoming, friendly, supportive colleagues • A diverse and inclusive working environment • State of the art laboratory and manufacturing facilities Collaborate. Contribute. Change lives LI-SCM1 Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.